Source:http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/31
| Predicate | Object |
|---|---|
| rdf:type | |
| rdfs:label |
Nyamyc (Powder)
|
| dailymed-instance:dosage |
Very moist lesions are best treated with the topical dusting powder.<br/>Nyamyc���(Nystatin Topical Powder, USP)Adults and Pediatric Patients(Neonates and Older):: Apply to candidal lesions two or three times daily until healing is complete. For fungal infection of the feet caused by Candida species, the powder should be dusted on the feet, as well as, in all foot wear.
|
| dailymed-instance:descripti... |
Nystatin is a polyene antifungal antibiotic obtained from Streptomyces nursei. Structural formula: Nystatin Nyamyc���(Nystatin Topical Powder, USP) is for dermatologic use. Nyamyc���(Nystatin Topical Powder, USP) contains 100,000 USP nystatin units per gram dispersed in talc.
|
| dailymed-instance:clinicalP... |
Pharmacokinetics: Nystatin is not absorbed from intact skin or mucous membrane.<br/>Microbiology: Nystatin is an antibiotic which is both fungistatic and fungicidal in vitro against a wide variety of yeasts and yeast-like fungi, including Candida albicans, C. parapsilosis, C. tropicalis, C. guilliermondi, C. pseudotropicalis, C. krusei, Torulopsis glabrata, Tricophyton rubrum, T. mentagrophytes. Nystatin acts by binding to sterols in the cell membrane of susceptible species resulting in a change in membrane permeability and the subsequent leakage of intracellular components. On repeated subculturing with increasing levels of nystatin, Candida albicans does not develop resistance to nystatin. Generally, resistance to nystatin does not develop during therapy.However, other species of Candida (C. tropicalis, C. guilliermondi, C. krusei, and C. stellatoides) become quite resistant on treatment with nystatin and simultaneously become cross resistant to amphotericin as well. This resistance is lost when the antibiotic is removed. Nystatin exhibits no appreciable activity against bacteria, protozoa, or viruses.
|
| dailymed-instance:activeIng... | |
| dailymed-instance:contraind... |
Nyamyc���(Nystatin Topical Powder, USP) is contraindicated in patients with a history of hypersensitivity to any of its components.
|
| dailymed-instance:supply |
Nyamyc���(Nystatin Topical Powder, USP): 100,000 units nystatin per gram in 15 g (NDC 0832-0465-15) and 30 g (NDC-0832-0465-30) plastic squeeze bottles.
|
| dailymed-instance:genericDr... | |
| dailymed-instance:activeMoi... | |
| dailymed-instance:inactiveI... | |
| dailymed-instance:precautio... |
General: Nyamyc���(Nystatin Topical Powder, USP) should not be used for the treatment of systemic, oral, intravaginal or ophthalmic infections. If irritation or sensitization develops, treatment should be discontinued and appropriate measures taken as indicated. It is recommended that KOH smears, cultures, or other diagnostic methods be used to confirm the diagnosis of cutaneous or mucocutaneous candidiasis and to rule out infection caused by other pathogens.
|
| dailymed-instance:genericMe... |
Nystatin
|
| dailymed-instance:fullName |
Nyamyc (Powder)
|
| dailymed-instance:adverseRe... |
The frequency of adverse events reported in patients using nystatin topical preparations is less than 0.1%. The more common events that were reported include allergic reactions, burning, itching, rash, eczema, and pain on application.
|
| dailymed-instance:indicatio... |
Nyamyc���(Nystatin Topical Powder, USP) is indicated in the treatment of cutaneous or mucocutaneous mycotic infections caused by Candida albicans and other susceptible Candida species. This preparation is not indicated for systemic, oral, intravaginal or ophthalmic use.
|
| dailymed-instance:represent... | |
| dailymed-instance:routeOfAd... | |
| dailymed-instance:name |
Nyamyc
|